{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:45:54Z","timestamp":1792752354609,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004099","name":"National League Against Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.jsbmb.2026.107137","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:13:33Z","timestamp":1792451613000},"page":"107137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Three decades of liver X receptor agonist chemistry: Structural motifs, structure-activity relationship, and therapeutic prospects"],"prefix":"10.1016","volume":"266","author":[{"given":"Norberta","family":"Delporte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Lagarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Chalard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silv\u00e8re","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6587-9501","authenticated-orcid":false,"given":"Amalia","family":"Trousson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9890-2392","authenticated-orcid":false,"given":"Jean-Marc A.","family":"Lobaccaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.jsbmb.2026.107137_bib1","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1021\/jm500442z","article-title":"The medicinal chemistry of Liver X Receptor (LXR) modulators","volume":"57","author":"Tice","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.772435","article-title":"Natural products targeting liver X receptors or farnesoid X receptor","volume":"12","author":"She","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jsbmb.2026.107137_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2025.102967","article-title":"Liver X receptors and the hallmarks of aging: From molecular mechanisms to therapeutic opportunities","volume":"114","author":"Poirot","year":"2026","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.jsbmb.2026.107137_bib4","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1146\/annurev.cellbio.16.1.459","article-title":"The role of orphan nuclear receptors in the regulation of cholesterol homeostasis","volume":"16","author":"Repa","year":"2000","journal-title":"Annu. Rev. Cell. Dev. Biol."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib5","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1101\/gad.9.9.1033","article-title":"LXR, a nuclear receptor that defines a distinct retinoid response pathway","volume":"9","author":"Willy","year":"1995","journal-title":"Genes. Dev."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib6","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.3390\/biomedicines10092165","article-title":"Liver X Receptor Regulation of Glial Cell Functions in the CNS","volume":"10","author":"Song","year":"2022","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0378-1119(94)90080-9","article-title":"NER, a new member of the gene family encoding the human steroid hormone nuclear receptor","volume":"147","author":"Shinar","year":"1994","journal-title":"Gene"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.mce.2011.08.036","article-title":"Selective liver X receptor modulators (SLiMs): What use in human health?","volume":"351","author":"Viennois","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1242\/jcs.00247","article-title":"The nuclear receptor superfamily","volume":"116","author":"Robinson-Rechavi","year":"2003","journal-title":"J. Cell. Sci."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib10","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1172\/JCI27883","article-title":"Liver X receptors as integrators of metabolic and inflammatory signaling","volume":"116","author":"Zelcer","year":"2006","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jsbmb.2026.107137_bib11","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1038\/383728a0","article-title":"DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha","volume":"383","author":"Janowski","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.jsbmb.2026.107137_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S0092-8674(00)81432-4","article-title":"Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha","volume":"93","author":"Peet","year":"1998","journal-title":"Cell"},{"issue":"16","key":"10.1016\/j.jsbmb.2026.107137_bib13","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1111\/bph.15286","article-title":"Screening for liver X receptor modulators: Where are we and for what use?","volume":"178","author":"Bu\u00f1ay","year":"2021","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1210\/me.2002-0399","article-title":"Liver X Receptors Interact with Corepressors to Regulate Gene Expression","volume":"17","author":"Hu","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"17","key":"10.1016\/j.jsbmb.2026.107137_bib15","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1073\/pnas.0500299102","article-title":"Structural insights into the interaction and activation of histone deacetylase 3 by nuclear receptor corepressors","volume":"102","author":"Codina","year":"2005","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6548","key":"10.1016\/j.jsbmb.2026.107137_bib16","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/377454a0","article-title":"A transcriptional co-repressor that interacts with nuclear hormone receptors","volume":"377","author":"Chen","year":"1995","journal-title":"Nature"},{"issue":"6548","key":"10.1016\/j.jsbmb.2026.107137_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/377397a0","article-title":"Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor","volume":"377","author":"H\u00f6rlein","year":"1995","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/me.2002-0258","article-title":"Transactivation Functions of the N-Terminal Domains of Nuclear Hormone Receptors: Protein Folding and Coactivator Interactions","volume":"17","author":"Kumar","year":"2003","journal-title":"Mol. Endocrinol."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1161\/01.ATV.0000121202.72593.da","article-title":"Role of p160 Coactivator Complex in the Activation of Liver X Receptor","volume":"24","author":"Huuskonen","year":"2004","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.jsbmb.2026.107137_bib20","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1042\/bj20021665","article-title":"Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor \u03b3 co-activator 1 alpha","volume":"371","author":"Oberkofler","year":"2003","journal-title":"Biochem. J."},{"issue":"14","key":"10.1016\/j.jsbmb.2026.107137_bib21","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1161\/CIRCULATIONAHA.108.782300","article-title":"Activation of Liver X Receptors Promotes Neuroprotection and Reduces Brain Inflammation in Experimental Stroke","volume":"118","author":"Morales","year":"2008","journal-title":"Circulation"},{"issue":"23-24","key":"10.1016\/j.jsbmb.2026.107137_bib22","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1016\/j.febslet.2008.08.035","article-title":"Treatment with LXR agonists after focal cerebral ischemia prevents brain damage","volume":"582","author":"Sironi","year":"2008","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.cell.2008.04.052","article-title":"LXR Signaling Couples Sterol Metabolism to Proliferation in the Acquired Immune Response","volume":"134","author":"Bensinger","year":"2008","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107137_bib24","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1182\/blood-2006-08-043422","article-title":"Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin","volume":"109","author":"Geyeregger","year":"2007","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nm820","article-title":"Reciprocal regulation of inflammation and lipid metabolism by liver X receptors","volume":"9","author":"Joseph","year":"2003","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib26","doi-asserted-by":"crossref","first-page":"10443","DOI":"10.1074\/jbc.M213071200","article-title":"Liver X Receptor-dependent Repression of Matrix Metalloproteinase-9 Expression in Macrophages","volume":"278","author":"Castrillo","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib27","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1172\/JCI28400","article-title":"Liver X receptors regulate adrenal cholesterol balance","volume":"116","author":"Cummins","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107137_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202307201","article-title":"Reprogramming of the LXR\u03b1 Transcriptome Sustains Macrophage Secondary Inflammatory Responses","volume":"11","author":"Vladimir De La Rosa","year":"2024","journal-title":"Adv. Sci."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107137_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1714518115","article-title":"Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages","volume":"115","author":"Muse","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib30","doi-asserted-by":"crossref","DOI":"10.1128\/MCB.00376-18","article-title":"Common and Differential Transcriptional Actions of Nuclear Receptors Liver X Receptors and in Macrophages","volume":"39","author":"Ram\u00f3n-V\u00e1zquez","year":"2019","journal-title":"Mol. Cell. Biol."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib31","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1038\/s44321-025-00251-1","article-title":"LXR pathway drives hormonal response intensity in polycystic ovary syndrome","volume":"17","author":"Dallel","year":"2025","journal-title":"EMBO Mol. Med."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib32","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1073\/pnas.0830671100","article-title":"Activation of liver X receptor improves glucose tolerance through coordinate regulation of glucose metabolism in liver and adipose tissue","volume":"100","author":"Laffitte","year":"2003","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"22","key":"10.1016\/j.jsbmb.2026.107137_bib33","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1101\/gad.850400","article-title":"Role of LXRs in control of lipogenesis","volume":"14","author":"Schultz","year":"2000","journal-title":"Genes. Dev."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107137_bib34","doi-asserted-by":"crossref","first-page":"7604","DOI":"10.1073\/pnas.112059299","article-title":"Synthetic LXR ligand inhibits the development of atherosclerosis in mice","volume":"99","author":"Joseph","year":"2002","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"25","key":"10.1016\/j.jsbmb.2026.107137_bib35","doi-asserted-by":"crossref","first-page":"10601","DOI":"10.1073\/pnas.0701096104","article-title":"Attenuation of neuroinflammation and Alzheimer\u2019s disease pathology by liver x receptors","volume":"104","author":"Zelcer","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib36","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1002\/jnr.21038","article-title":"Liver X receptor activation decreases the severity of experimental autoimmune encephalomyelitis","volume":"84","author":"Hindinger","year":"2006","journal-title":"J. Neurosci. Res."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107137_bib37","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1194\/jlr.M300135-JLR200","article-title":"The LXR ligand T0901317 induces severe lipogenesis in the db\/db diabetic mouse","volume":"44","author":"Chisholm","year":"2003","journal-title":"J. Lipid Res."},{"issue":"24","key":"10.1016\/j.jsbmb.2026.107137_bib38","doi-asserted-by":"crossref","first-page":"23024","DOI":"10.1074\/jbc.M412564200","article-title":"LXR\u03b2 Is Required for Adipocyte Growth, Glucose Homeostasis, and \u03b2 Cell Function","volume":"280","author":"Gerin","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1-2","key":"10.1016\/j.jsbmb.2026.107137_bib39","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jneuroim.2006.11.007","article-title":"Liver X receptor and retinoid X receptor agonists inhibit inflammatory responses of microglia and astrocytes","volume":"183","author":"Zhang-Gandhi","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib40","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.gde.2008.07.016","article-title":"Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors","volume":"18","author":"Hong","year":"2008","journal-title":"Curr. Opin. Genet. Dev."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib41","first-page":"3900","article-title":"Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice","volume":"117","author":"Yvan-Charvet","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib42","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/me.2006-0277","article-title":"Multiple Roles of the Nuclear Receptors for Oxysterols Liver X Receptor to Maintain Male Fertility","volume":"21","author":"Volle","year":"2007","journal-title":"Mol. Endocrinol."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib43","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.1210\/en.2015-1382","article-title":"Identification of the Functions of Liver X Receptor-\u03b2 in Sertoli Cells Using a Targeted Expression-Rescue Model","volume":"156","author":"Maqdasy","year":"2015","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib44","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1210\/en.2008-1519","article-title":"Absence of Nuclear Receptors for Oxysterols Liver X Receptor Induces Ovarian Hyperstimulation Syndrome in Mice","volume":"150","author":"Mouzat","year":"2009","journal-title":"Endocrinology"},{"issue":"1-2","key":"10.1016\/j.jsbmb.2026.107137_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mce.2012.06.009","article-title":"Emerging roles for LXRs and LRH-1 in female reproduction","volume":"368","author":"Mouzat","year":"2013","journal-title":"Mol. Cell. Endocrinol."},{"issue":"13","key":"10.1016\/j.jsbmb.2026.107137_bib46","doi-asserted-by":"crossref","first-page":"6482","DOI":"10.1158\/0008-5472.CAN-06-0632","article-title":"Inhibition of Tumor Growth and Progression of LNCaP Prostate Cancer Cells in Athymic Mice by Androgen and Liver X Receptor Agonist","volume":"66","author":"Chuu","year":"2006","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.jsbmb.2026.107137_bib47","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1038\/onc.2010.30","article-title":"Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells","volume":"29","author":"Pommier","year":"2010","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib48","article-title":"Induction of pyroptosis in colon cancer cells by LXR\u03b2","volume":"2","author":"R\u00e9b\u00e9","year":"2015","journal-title":"Mol. Cell. Oncol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/receptors2010003","article-title":"A Novel Liver X Receptor Inverse Agonist Impairs Cholesterol and Phospholipid Metabolism and Induces Apoptosis and Necroptosis in Pancreatic Ductal Adenocarcinoma Cells","volume":"2","author":"Widmann","year":"2023","journal-title":"Receptors"},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107137_bib50","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1002\/1878-0261.13476","article-title":"Liver X receptors induce antiproliferative effects in basal-like breast cancer","volume":"17","author":"Haugen","year":"2023","journal-title":"Mol. Oncol."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib51","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/jcmm.13974","article-title":"Liver X receptor activation reduces gastric cancer cell proliferation by suppressing Wnt signalling via LXR \u03b2 relocalization","volume":"23","author":"Wang","year":"2018","journal-title":"J. Cell. Mol. Med."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib52","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/CAD.0000000000000758","article-title":"Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro","volume":"30","author":"Lou","year":"2019","journal-title":"Anticancer. Drugs"},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib53","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1097\/CAD.0000000000000532","article-title":"Liver X receptors agonist T0901317 downregulates matrix metalloproteinase-9 expression in non-small-cell lung cancer by repressing nuclear factor-\u03baB","volume":"28","author":"Chen","year":"2017","journal-title":"Anticancer. Drugs"},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib54","first-page":"885","article-title":"Snail mediates crosstalk between TGF\u03b2 and LXR\u03b1 in hepatocellular carcinoma","volume":"25","author":"Bellomo","year":"2018","journal-title":"Cell. Death Differ."},{"issue":"16","key":"10.1016\/j.jsbmb.2026.107137_bib55","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3390\/cancers16162776","article-title":"Liver X Receptors Enhance Epithelial to Mesenchymal Transition in Metastatic Prostate Cancer Cells","volume":"16","author":"Bouchareb","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neo.2019.08.002","article-title":"Liver X Receptor Agonism Sensitizes a Subset of Hepatocellular Carcinoma to Sorafenib by Dual-Inhibiting MET and EGFR","volume":"22","author":"Shao","year":"2020","journal-title":"Neoplasia"},{"key":"10.1016\/j.jsbmb.2026.107137_bib57","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1038\/s41388-021-01720-w","article-title":"Liver x receptor alpha drives chemoresistance in response to side-chain hydroxycholesterols in triple negative breast cancer","volume":"40","author":"Hutchinson","year":"2021","journal-title":"Oncog"},{"key":"10.1016\/j.jsbmb.2026.107137_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1386102","article-title":"Liver X Receptors (LXRs) in cancer-an Eagle\u2019s view on molecular insights and therapeutic opportunities","volume":"12","author":"Ramalingam","year":"2024","journal-title":"Front. Cell. Dev. Biol."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nm.2074","article-title":"Tumor-mediated liver X receptor-\u03b1 activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses","volume":"16","author":"Villablanca","year":"2009","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib60","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2015.05.007","article-title":"Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis","volume":"28","author":"Flaveny","year":"2015","journal-title":"Cancer Cell."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107137_bib61","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1021\/acschembio.0c00546","article-title":"Screening of Focused Compound Library Targeting Liver X Receptors in Pancreatic Cancer Identified Ligands with Inverse Agonist and Degrader Activity","volume":"15","author":"Karaboga","year":"2020","journal-title":"ACS Chem. Biol."},{"issue":"24","key":"10.1016\/j.jsbmb.2026.107137_bib62","doi-asserted-by":"crossref","first-page":"9622","DOI":"10.3390\/ijms21249622","article-title":"Novel Liver X Receptor Ligand GAC0001E5 Disrupts Glutamine Metabolism and Induces Oxidative Stress in Pancreatic Cancer Cells","volume":"21","author":"Srivastava","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/biom13020345","article-title":"Liver X Receptor Inverse Agonist GAC0001E5 Impedes Glutaminolysis and Disrupts Redox Homeostasis in Breast Cancer Cells","volume":"13","author":"Premaratne","year":"2023","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib64","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1021\/acs.jcim.9b00292","article-title":"Structurally Selective Mechanism of Liver X Receptor Ligand: In Silico and In vitro Studies","volume":"59","author":"Ding","year":"2019","journal-title":"J. Chem. Inf. Model."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib65","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1124\/jpet.108.142687","article-title":"Antiatherosclerotic Effects of a Novel Synthetic Tissue-Selective Steroidal Liver X Receptor Agonist in Low-Density Lipoprotein Receptor-Deficient Mice","volume":"327","author":"Peng","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107137_bib66","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1021\/jm0255116","article-title":"Identification of a Nonsteroidal Liver X Receptor Agonist through Parallel Array Synthesis of Tertiary Amines","volume":"45","author":"Collins","year":"2002","journal-title":"J. Med. Chem."},{"issue":"18","key":"10.1016\/j.jsbmb.2026.107137_bib67","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1093\/emboj\/cdg456","article-title":"Crystal structure of the heterodimeric complex of LXR and RXR ligand-binding domains in a fully agonistic conformation","volume":"22","author":"Svensson","year":"2003","journal-title":"EMBO J."},{"issue":"16","key":"10.1016\/j.jsbmb.2026.107137_bib68","doi-asserted-by":"crossref","first-page":"3436","DOI":"10.1016\/j.bmc.2016.05.048","article-title":"Discovery of a 2-hydroxyacetophenone derivative as an outstanding linker to enhance potency and \u03b2-selectivity of liver X receptor agonist","volume":"24","author":"Koura","year":"2016","journal-title":"Bioorg. Med. Chem."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib69","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1021\/acsmedchemlett.6b00234","article-title":"Discovery of Highly Potent Liver X Receptor \u03b2 Agonists","volume":"7","author":"Kick","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib70","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1074\/jbc.272.6.3137","article-title":"Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway","volume":"272","author":"Lehmann","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1073\/pnas.96.1.266","article-title":"Structural requirements of ligands for the oxysterol liver X receptors LXR alpha and LXR","volume":"96","author":"Janowski","year":"1999","journal-title":"beta. Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jsbmb.2026.107137_bib72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0960-894X(98)00016-X","article-title":"An alternative synthesis of 4,4-dimethyl-5alpha-cholesta-8,14,24-tien-3beta-ol, an intermediate in sterol biosynthesis and a reported activator of meiosis and of nuclear orphan receptor LXR alpha","volume":"8","author":"Ruan","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib73","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1095\/biolreprod58.5.1297","article-title":"I. Meiosis-activating sterol promotes resumption of meiosis in mouse oocytes cultured in vitro in contrast to related oxysterols","volume":"58","author":"Gr\u00f8ndahl","year":"1998","journal-title":"Biol. Reprod."},{"issue":"38","key":"10.1016\/j.jsbmb.2026.107137_bib74","doi-asserted-by":"crossref","first-page":"27816","DOI":"10.1074\/jbc.M603781200","article-title":"Sterol Intermediates from Cholesterol Biosynthetic Pathway as Liver X Receptor Ligands","volume":"281","author":"Yang","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib75","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1038\/ncomms2835","article-title":"Dendrogenin A arises from cholesterol and histamine metabolism and shows cell differentiation and anti-tumour properties","volume":"4","author":"De Medina","year":"2013","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib76","doi-asserted-by":"crossref","DOI":"10.1002\/jev2.12211","article-title":"Targeting the liver X receptor with dendrogenin A differentiates tumour cells to secrete immunogenic exosome-enriched vesicles","volume":"11","author":"Record","year":"2022","journal-title":"J. Extracell. Vesicles"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib77","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/s41467-017-01948-9","article-title":"Dendrogenin A drives LXR to trigger lethal autophagy in cancers","volume":"8","author":"Segala","year":"2017","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.jsbmb.2026.107137_bib78","doi-asserted-by":"crossref","first-page":"7161","DOI":"10.1021\/jm800799q","article-title":"Indazole-Based Liver X Receptor (LXR) Modulators with Maintained Atherosclerotic Lesion Reduction Activity but Diminished Stimulation of Hepatic Triglyceride Synthesis","volume":"51","author":"Wrobel","year":"2008","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib79","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1194\/jlr.M900037-JLR200","article-title":"LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse","volume":"50","author":"Quinet","year":"2009","journal-title":"J. Lipid Res."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib80","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/eurheartj\/ehr136","article-title":"Synergistic effect of liver X receptor activation and simvastatin on plaque regression and stabilization: an magnetic resonance imaging study in a model of advanced atherosclerosis","volume":"33","author":"Giannarelli","year":"2012","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib81","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/0091270009335768","article-title":"Safety, Pharmacokinetics, and Pharmacodynamics of Single Doses of LXR-623, a Novel Liver X-Receptor Agonist, in Healthy Participants","volume":"49","author":"Katz","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.jsbmb.2026.107137_bib82","article-title":"Single ascending dose study of the safety, tolerability, and pharmacokinetics of LXR-623 administered orally to healthy subjects","year":"2006","journal-title":"Clin. Gov. identifier NCT00366522"},{"key":"10.1016\/j.jsbmb.2026.107137_bib83","article-title":"A randomized, placebo-controlled, single ascending dose study to assess the safety, tolerability and pharmacokinetics of CS-8080 in healthy volunteers","author":"Sankyo","year":"2008","journal-title":"Clin. Gov. identifier NCT00613431"},{"key":"10.1016\/j.jsbmb.2026.107137_bib84","article-title":"A randomized, placebo-controlled, multiple ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-8080 in healthy volunteers","author":"Sankyo","year":"2008","journal-title":"Clin. Gov. identifier NCT00796575"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib85","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.bmcl.2014.11.029","article-title":"Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXR\u03b2","volume":"25","author":"Kick","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2026.107137_bib86","article-title":"Placebo-controlled, ascending, multiple-dose study to evaluate the safety, pharmacokinetics and pharmacodynamics of BMS-779788 in healthy subjects","author":"Squibb","year":"2009","journal-title":"Clin. Gov. identifier NCT00836602"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib87","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.114.219923","article-title":"Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXR\u03b1 Activity and a Favorable Window in Nonhuman Primates","volume":"352","author":"Kirchgessner","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib88","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.cmet.2016.07.016","article-title":"Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils","volume":"24","author":"Kirchgessner","year":"2016","journal-title":"Cell. Metab."},{"key":"10.1016\/j.jsbmb.2026.107137_bib89","article-title":"A site and subject blinded study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BMS-852927 in patients with primary hypercholesterolemia on a stable dose of statin therapy","author":"Squibb","year":"2012","journal-title":"Clin. Gov. identifier NCT01651273"},{"key":"10.1016\/j.jsbmb.2026.107137_bib90","unstructured":"Ralexar Therapeutics, Inc. A multicenter, randomized, double-blind, bilateral, vehicle-controlled study of the safety and efficacy of ALX-101 topical gel administered twice daily in adult and adolescent subjects with moderate atopic dermatitis Clin. Gov. identifier NCT031753542017."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib91","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2017.12.026","article-title":"LXR\/ApoE Activation Restricts Innate Immune Suppression in Cancer","volume":"172","author":"Tavazoie","year":"2018","journal-title":"Cell"},{"issue":"15_","key":"10.1016\/j.jsbmb.2026.107137_bib92","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.2018.36.15_suppl.3095","article-title":"Pharmacodynamic and clinical activity of RGX-104, a first-in-class immunotherapy targeting the liver-X nuclear hormone receptor (LXR), in patients with refractory malignancies","volume":"36","author":"Mita","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.jsbmb.2026.107137_bib93","unstructured":"Inspirna, Inc. (formerly Rgenix, Inc.). A phase 1 study of RGX-104, a small molecule LXR agonist, as a single agent and as combination therapy in patients with advanced solid malignancies and expansion in select malignancies. ClinicalTrials.gov identifier NCT02922764. 2016."},{"key":"10.1016\/j.jsbmb.2026.107137_bib94","unstructured":"U.N.C. Lineberger Comprehensive Cancer Center, in collaboration with AstraZeneca and Rgenix, Inc. A pilot window of opportunity study evaluating durvalumab (MEDI4736) in combination with platinum doublet chemotherapy followed by evaluation of durvalumab (MEDI4736) in combination with platinum doublet chemotherapy and abequolixron (RGX-104) in non-small cell lung cancer. ClinicalTrials.gov identifier NCT05911308. 2024."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib95","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1021\/acs.jmedchem.5b02029","article-title":"Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) \u03b2 Agonist","volume":"59","author":"Zheng","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib96","unstructured":"Vitae Pharmaceuticals, Inc. A randomized, double-blind, vehicle-controlled ascending multiple dose and clinical proof-of-concept study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VTP-38543 in adult patients with mild to moderate atopic dermatitis. ClinicalTrials.gov identifier NCT02655679. 2015."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib97","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.anai.2018.03.013","article-title":"Effect of short-term liver X receptor activation on epidermal barrier features in mild to moderate atopic dermatitis","volume":"120","author":"Czarnowicki","year":"2018","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib98","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1016\/j.bmcl.2007.03.076","article-title":"Discovery and structure\u2013activity relationship studies of indole derivatives as liver X receptor (LXR) agonists","volume":"17","author":"Bakir","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib99","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.febslet.2007.03.047","article-title":"T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR","volume":"581","author":"Mitro","year":"2007","journal-title":"FEBS Lett."},{"issue":"1-2","key":"10.1016\/j.jsbmb.2026.107137_bib100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ymgme.2004.07.007","article-title":"T0901317 is a dual LXR\/FXR agonist","volume":"83","author":"Houck","year":"2004","journal-title":"Mol. Genet. Metab."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib101","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1124\/mol.109.060905","article-title":"The Benzenesulfoamide T0901317 [N-(2,2,2-Trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide] Is a Novel Retinoic Acid Receptor-Related Orphan Receptor-\u03b1\/\u03b3 Inverse Agonist","volume":"77","author":"Kumar","year":"2010","journal-title":"Mol. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib102","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2131\/jts.38.309","article-title":"T0901317, a potent LXR agonist, is an inverse agonist of CAR","volume":"38","author":"Kanno","year":"2013","journal-title":"J. Toxicol. Sci."},{"issue":"21","key":"10.1016\/j.jsbmb.2026.107137_bib103","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1158\/0008-5472.CAN-04-2332","article-title":"Antiproliferative Effect of Liver X Receptor Agonists on LNCaP Human Prostate Cancer Cells","volume":"64","author":"Fukuchi","year":"2004","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib104","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.bbrc.2007.03.116","article-title":"The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells","volume":"357","author":"Chuu","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib105","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.jnutbio.2011.06.009","article-title":"Lycopene and the LXR\u03b1 agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPAR\u03b3-LXR\u03b1-ABCA1 pathway","volume":"23","author":"Yang","year":"2012","journal-title":"J. Nutr. Biochem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib106","first-page":"3007","article-title":"LXR Agonists and ABCG1-dependent Cholesterol Efflux in MCF-7 Breast Cancer Cells: Relation to Proliferation and Apoptosis","volume":"32","author":"Roz","year":"2012","journal-title":"Anticancer. Res."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib107","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bcp.2008.10.007","article-title":"Suppression of \u03b2-catenin signaling by liver X receptor ligands","volume":"77","author":"Uno","year":"2009","journal-title":"Biochem. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.prp.2016.04.013","article-title":"Liver X receptor activation inhibits PC-3 prostate cancer cells via the beta-catenin pathway","volume":"213","author":"Youlin","year":"2017","journal-title":"Pathol. - Res. Pract."},{"issue":"12","key":"10.1016\/j.jsbmb.2026.107137_bib109","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1038\/cdd.2014.117","article-title":"Liver X receptor \u03b2 activation induces pyroptosis of human and murine colon cancer cells","volume":"21","author":"Derang\u00e8re","year":"2014","journal-title":"Cell. Death Differ."},{"issue":"40","key":"10.1016\/j.jsbmb.2026.107137_bib110","doi-asserted-by":"crossref","first-page":"38821","DOI":"10.1074\/jbc.M304842200","article-title":"The Three-dimensional Structure of the Liver X Receptor \u03b2 Reveals a Flexible Ligand-binding Pocket That Can Accommodate Fundamentally Different Ligands","volume":"278","author":"F\u00e4rneg\u00e5rdh","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.116792","article-title":"Design, synthesis and structure\u2013activity relationship of 4-(1,1,1,3,3,3-hexafluoro-2-hydroxyisoprop-2-yl)phenylsilane derivatives as liver X receptor agonists","volume":"66","author":"Namba","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib112","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1053\/j.gastro.2013.02.005","article-title":"Liver X Receptors Inhibit Proliferation of Human Colorectal Cancer Cells and Growth of Intestinal Tumors in Mice","volume":"144","author":"Lo Sasso","year":"2013","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib113","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3443","article-title":"Liver \u00d7 receptor ligands disrupt breast cancer cell proliferation through an E2F-mediated mechanism","volume":"15","author":"Nguyen-Vu","year":"2013","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jsbmb.2026.107137_bib114","article-title":"Antiproliferative Effects and Mechanisms of Liver X Receptor Ligands in Pancreatic Ductal Adenocarcinoma Cells","volume":"9","author":"Candelaria","year":"2014"},{"key":"10.1016\/j.jsbmb.2026.107137_bib115","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.biocel.2016.07.007","article-title":"LXR agonist regulates the proliferation and apoptosis of human T-Cell acute lymphoblastic leukemia cells via the SOCS3 pathway","volume":"78","author":"Zhang","year":"2016","journal-title":"Int. J. Biochem. Cell. Biol."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib116","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1158\/2159-8290.CD-11-0102","article-title":"An LXR Agonist Promotes Glioblastoma Cell Death through Inhibition of an EGFR\/AKT\/SREBP-1\/LDLR\u2013Dependent Pathway","volume":"1","author":"Guo","year":"2011","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib117","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.cell.2014.01.038","article-title":"Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation","volume":"156","author":"Pencheva","year":"2014","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib118","doi-asserted-by":"crossref","first-page":"14336","DOI":"10.1002\/jcb.28558","article-title":"Activation of LXR\u03b2 inhibits proliferation, promotes apoptosis, and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4","volume":"120","author":"Liu","year":"2019","journal-title":"J. Cell. Biochem."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib119","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jmb.2010.04.005","article-title":"X-Ray Structures of the LXR\u03b1 LBD in Its Homodimeric Form and Implications for Heterodimer Signaling","volume":"399","author":"Fradera","year":"2010","journal-title":"J. Mol. Biol."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib120","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1161\/ATVBAHA.109.195693","article-title":"Tissue-Specific Liver X Receptor Activation Promotes Macrophage Reverse Cholesterol Transport In vivo","volume":"30","author":"Yasuda","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib121","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.bmcl.2009.01.004","article-title":"Synthesis and SAR of potent LXR agonists containing an indole pharmacophore","volume":"19","author":"Washburn","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107137_bib122","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1021\/jm0609566","article-title":"Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists","volume":"49","author":"Hu","year":"2006","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib123","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bmcl.2007.11.013","article-title":"Carboxylic acid based quinolines as liver X receptor modulators that have LXR\u03b2 receptor binding selectivity","volume":"18","author":"Hu","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib124","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/j.bmc.2008.12.048","article-title":"Biarylether amide quinolines as liver X receptor agonists","volume":"17","author":"Bernotas","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"10","key":"10.1016\/j.jsbmb.2026.107137_bib125","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1016\/j.bmc.2009.04.012","article-title":"Discovery and SAR of cinnolines\/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXR\u03b2","volume":"17","author":"Hu","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"23","key":"10.1016\/j.jsbmb.2026.107137_bib126","doi-asserted-by":"crossref","first-page":"8086","DOI":"10.1016\/j.bmc.2009.10.001","article-title":"4-(3-aryloxyaryl)quinoline alcohols are liver X receptor agonists","volume":"17","author":"Bernotas","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib127","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.bmcl.2009.11.062","article-title":"Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXR\u03b2 and low blood-brain penetration","volume":"20","author":"Hu","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.bmcl.2009.10.132","article-title":"4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists","volume":"20","author":"Bernotas","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib129","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.bmcl.2010.03.031","article-title":"Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists","volume":"20","author":"Ullrich","year":"2010","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107137_bib130","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1021\/jm100034x","article-title":"Identification of Phenylsulfone-Substituted Quinoxaline (WYE-672) as a Tissue Selective Liver X-receptor (LXR) Agonist","volume":"53","author":"Hu","year":"2010","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib131","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bmcl.2015.01.047","article-title":"Design and discovery of 2-oxochromene derivatives as liver X receptor \u03b2-selective agonists","volume":"25","author":"Matsuda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"6","key":"10.1016\/j.jsbmb.2026.107137_bib132","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3390\/molecules23061349","article-title":"Identfication of Potent LXR\u03b2-Selective Agonists without LXR\u03b1 Activation by In Silico Approaches","volume":"23","author":"Chen","year":"2018","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib133","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/endo.143.7.8907","article-title":"A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a)","volume":"143","author":"Menke","year":"2002","journal-title":"Endocrinology"},{"issue":"15","key":"10.1016\/j.jsbmb.2026.107137_bib134","doi-asserted-by":"crossref","first-page":"6033","DOI":"10.1021\/jm301913k","article-title":"Synthesis and Identification of New Flavonoids Targeting Liver X Receptor \u03b2 Involved Pathway as Potential Facilitators of A\u03b2 Clearance with Reduced Lipid Accumulation","volume":"56","author":"Hu","year":"2013","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/ci400682b","article-title":"Discovery of New Liver X Receptor Agonists by Pharmacophore Modeling and Shape-Based Virtual Screening","volume":"54","author":"Temml","year":"2014","journal-title":"J. Chem. Inf. Model."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib136","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.bmcl.2018.12.025","article-title":"Development of novel liver X receptor modulators based on a 1,2,4-triazole scaffold","volume":"29","author":"Goher","year":"2019","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"17","key":"10.1016\/j.jsbmb.2026.107137_bib137","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1021\/jm050532w","article-title":"Discovery of Substituted Maleimides as Liver X Receptor Agonists and Determination of a Ligand-Bound Crystal Structure","volume":"48","author":"Jaye","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib138","series-title":"Patent WO2006073363A1","article-title":"Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators","year":"2006"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib139","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/j.1476-5381.2010.01168.x","article-title":"Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE*3Leiden mice without affecting liver or plasma triglyceride levels","volume":"162","author":"Van Der Hoorn","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib140","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/ejhf.243","article-title":"The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects","volume":"17","author":"Cannon","year":"2015","journal-title":"Eur. J. Heart Fail."},{"issue":"14","key":"10.1016\/j.jsbmb.2026.107137_bib141","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.019473","article-title":"Liver X Receptor Agonist AZ876 Induces Beneficial Endogenous Cardiac Lipid Reprogramming and Protects Against Isoproterenol-Induced Cardiac Damage","volume":"10","author":"Ritter","year":"2021","journal-title":"J. Am. Heart Assoc."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib142","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1021\/acs.jmedchem.4c02712","article-title":"Uncovering \u03b1-Selectivity for Liver X Receptor Agonists for Lipotoxic Cancer Therapies","volume":"68","author":"Galvez B. Pedreira","year":"2025","journal-title":"J. Med. Chem."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107137_bib143","doi-asserted-by":"crossref","first-page":"5044","DOI":"10.1016\/j.bmcl.2016.08.089","article-title":"Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core","volume":"26","author":"Tice","year":"2016","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.jsbmb.2026.107137_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112240","article-title":"Discovery of new LXR\u03b2 agonists as glioblastoma inhibitors","volume":"194","author":"Chen","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib145","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1021\/acs.jmedchem.6b00176","article-title":"Identification and in vivo Evaluation of Liver X Receptor \u03b2-Selective Agonists for the Potential Treatment of Alzheimer\u2019s Disease","volume":"59","author":"Stachel","year":"2016","journal-title":"J. Med. Chem."},{"issue":"s2","key":"10.1016\/j.jsbmb.2026.107137_bib146","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1365-2036.2006.02943.x","article-title":"Review article: the clinical pharmacology of proton pump inhibitors","volume":"23","author":"Sachs","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.jsbmb.2026.107137_bib147","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.bcp.2009.12.018","article-title":"Proton pump inhibitor Lansoprazole is a nuclear liver X receptor agonist","volume":"79","author":"Cronican","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jsbmb.2026.107137_bib148","article-title":"Defensive Effect of Lansoprazole in Dementia of AD Type in Mice Exposed to Streptozotocin and Cholesterol Enriched Diet","volume":"8","author":"Sodhi","year":"2013"},{"issue":"18","key":"10.1016\/j.jsbmb.2026.107137_bib149","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1016\/j.bmcl.2015.07.047","article-title":"Discovery and structure-guided optimization of tert-butyl 6-(phenoxymethyl)-3-(trifluoromethyl)benzoates as liver X receptor agonists","volume":"25","author":"Matsui","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107137_bib150","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1021\/acsmedchemlett.5b00170","article-title":"Styrylphenylphthalimides as Novel Transrepression-Selective Liver X Receptor (LXR) Modulators","volume":"6","author":"Nomura","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.jsbmb.2026.107137_bib151","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1002\/cmdc.201600305","article-title":"Development of Tetrachlorophthalimides as Liver X Receptor \u03b2 (LXR\u03b2)-Selective Agonists","volume":"11","author":"Nomura","year":"2016","journal-title":"ChemMedChem"},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib152","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.bmcl.2017.12.024","article-title":"Structural development of tetrachlorophthalimides as liver X receptor \u03b2 (LXR\u03b2)-selective agonists with improved aqueous solubility","volume":"28","author":"Nomura","year":"2018","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"23","key":"10.1016\/j.jsbmb.2026.107137_bib153","doi-asserted-by":"crossref","first-page":"4316","DOI":"10.3390\/molecules24234316","article-title":"Synthesis and In vitro Evaluation of Novel Liver X Receptor Agonists Based on Naphthoquinone Derivatives","volume":"24","author":"Nishioka","year":"2019","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.jsbmb.2026.107137_bib154","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.apsb.2016.03.005","article-title":"E17110 promotes reverse cholesterol transport with liver X receptor \u03b2 agonist activity in vitro","volume":"6","author":"Li","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.jsbmb.2026.107137_bib155","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/mol.116.105213","article-title":"Identification of a Novel Liver X Receptor Agonist that Regulates the Expression of Key Cholesterol Homeostasis Genes with Distinct Pharmacological Characteristics","volume":"91","author":"Li","year":"2017","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib156","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1039\/C4MB00718B","article-title":"Predicting selective liver X receptor \u03b2 agonists using multiple machine learning methods","volume":"11","author":"Li","year":"2015","journal-title":"Mol. Biosyst."},{"key":"10.1016\/j.jsbmb.2026.107137_bib157","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ejmech.2019.06.011","article-title":"Identify liver X receptor \u03b2 modulator building blocks by developing a fluorescence polarization-based competition assay","volume":"178","author":"Zhang","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib158","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1021\/acs.jmedchem.2c01661","article-title":"Discovery of Spiro[pyrrolidine-3,3\u2032-oxindole] LXR\u03b2 Agonists for the Treatment of Osteoporosis","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"issue":"11","key":"10.1016\/j.jsbmb.2026.107137_bib159","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200647","article-title":"Development of Light-Activated LXR Agonists","volume":"18","author":"Mukhopadhyay","year":"2023","journal-title":"ChemMedChem"},{"issue":"1","key":"10.1016\/j.jsbmb.2026.107137_bib160","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2025.2470310","article-title":"Synthesis and evaluation of 5, 6-dihydro-8 H -isoquinolino[1, 2- b]quinazolin-8-one derivatives as novel non-lipogenic ABCA1 up-regulators with inhibitory effects on macrophage-derived foam cell formation","volume":"40","author":"Yang","year":"2025","journal-title":"J. Enzym. Inhib. Med. Chem."},{"issue":"38","key":"10.1016\/j.jsbmb.2026.107137_bib161","doi-asserted-by":"crossref","first-page":"36091","DOI":"10.1074\/jbc.M304153200","article-title":"Induction of Intestinal ATP-binding Cassette Transporters by a Phytosterol-derived Liver X Receptor Agonist","volume":"278","author":"Kaneko","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib162","unstructured":"Liver X receptor agonists. Patent US2002\/0193357A1; 2002."},{"issue":"8","key":"10.1016\/j.jsbmb.2026.107137_bib163","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1476-5381.2011.01202.x","article-title":"A novel potent synthetic steroidal liver X receptor agonist lowers plasma cholesterol and triglycerides and reduces atherosclerosis in LDLR\u2013\/\u2013 mice","volume":"162","author":"Peng","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"13","key":"10.1016\/j.jsbmb.2026.107137_bib164","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137230","article-title":"Selective LXR agonist DMHCA corrects retinal and bone marrow dysfunction in type 2 diabetes","volume":"5","author":"Vieira","year":"2020","journal-title":"JCI Insight"},{"issue":"7","key":"10.1016\/j.jsbmb.2026.107137_bib165","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1096\/fj.201600244R","article-title":"Dissociated sterol-based liver X receptor agonists as therapeutics for chronic inflammatory diseases","volume":"30","author":"Yu","year":"2016","journal-title":"FASEB J."},{"key":"10.1016\/j.jsbmb.2026.107137_bib166","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jsbmb.2016.07.001","article-title":"Fluorinated oxysterol analogues: Synthesis, molecular modelling and LXR\u03b2 activity","volume":"165","author":"Rodriguez","year":"2017","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"5","key":"10.1016\/j.jsbmb.2026.107137_bib167","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.bmc.2018.01.025","article-title":"Synthesis and activity evaluation of a series of cholanamides as modulators of the liver X receptors","volume":"26","author":"Mart\u00ednez","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib168","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.steroids.2016.12.003","article-title":"Regulation of liver X receptor target genes by 22-functionalized oxysterols. Synthesis, in silico and in vitro evaluations","volume":"118","author":"Viktorsson","year":"2017","journal-title":"Steroids"},{"key":"10.1016\/j.jsbmb.2026.107137_bib169","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111647","article-title":"Discovery of tissue selective liver X receptor agonists for the treatment of atherosclerosis without causing hepatic lipogenesis","volume":"182","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jsbmb.2026.107137_bib170","doi-asserted-by":"crossref","DOI":"10.1016\/j.chemphyslip.2021.105151","article-title":"search for novel liver X receptors modulators by extending the structure\u2013activity relationships of cholenamide derivatives","volume":"241","author":"Pontini","year":"2021","journal-title":"Chem. Phys. Lipids"},{"issue":"2","key":"10.1016\/j.jsbmb.2026.107137_bib171","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.3390\/ijms24021290","article-title":"Identification of side chain oxidized sterols as novel liver X receptor agonists with therapeutic potential in the treatment of cardiovascular and neurodegenerative diseases","volume":"24","author":"Zhan","year":"2023","journal-title":"Int. J. Mol. Sci."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026002037?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076026002037?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T10:24:50Z","timestamp":1792751090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076026002037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":171,"alternative-id":["S0960076026002037"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107137","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Three decades of liver X receptor agonist chemistry: Structural motifs, structure-activity relationship, and therapeutic prospects","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2026.107137","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107137"}}